Case Report

Two Patients with Urachal Cancer with Multifocal Adenocarcinoma Recurrences in the Urothelium of the Prostatic and Penile Urethra

Laura E. Stokkel¹, Maurits L. van Montfoort², Hester H. van Boven², Laura S. Mertens², Bas W.G. van Rhijn²,³,*

¹Department of Urology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; ²Department of Pathology, Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; ³Department of Urology, Caritas St. Josef Medical Centre, University of Regensburg, Regensburg, Germany

Article info

Article history:
Accepted August 9, 2021

Associate Editor:
Guillaume Ploussard

Keywords:
Urachal cancer
Reurrence
Urethra
Urothelial
Adenocarcinoma

Abstract

We report two cases with recurrences of urachal adenocarcinoma (UrAC) in the urethra. Both patients had mucinous UrAC without metastasis, for which they were treated with en-bloc partial cystectomy and umbilicectomy. The first patient developed recurrence of UrAC in the distal urethra after 1 yr. Distal urethrectomy revealed multiple additional recurrences in the penile and prostatic urethra. The patient underwent radical cystoprostatectomy with en-bloc urethrectomy. At 5 mo after surgery, liver metastases were found. A search in our institutional database revealed a second patient who developed a solitary recurrence of UrAC in the prostatic urethra 8 yr after partial cystectomy. Radical cystoprostatectomy was performed. The patient subsequently experienced recurring UrAC in the urethra, which were treated with multiple surgeries and radiation. Unfortunately, local tumor control could not be achieved and the patient developed distant metastases 7 yr after cystoprostatectomy. Our two cases and four comparable cases reported in the literature indicate that urothelial spread of UrAC is rare but possible. It remains to be determined if UrAC spreads along the urothelium similar to urothelial cancer or if these multifocal urethral recurrences were the first sign of local metastasis. © 2021 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

* Corresponding author. Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.
Tel.: +31 20 512 2553; Fax: +31 20 512 2459.
E-mail address: b.v.rhijn@nki.nl (B. W.G. van Rhijn).
1. Case report

Uralch adenocarcinoma (UrAC) is a rare disease with an incidence of less than one in 10,000,000 [1]. It accounts for 0.2% of all bladder cancers and approximately 20–30% of bladder adenocarcinomas [2,3]. UrAC occurs in the persistent urachal remnant between the umbilicus and the bladder dome. In localized nonmetastatic urachal cancer, partial cystectomy with resection of the urachal remnant and umbilicus is the standard treatment [3,4]. Local bladder-dome recurrence after partial cystectomy occurs in approximately 10–15% of cases and metastatic progression as a sign of distant recurrence in 50–60% [3]. Other more or less local sites of recurrence include metastases to the pelvic lymph nodes and peritoneal spread and/or local metastases in the abdominal cavity and omentum [3]. So far, only four patients have been described, who had multifocal recurrent UrAC in the urothelium [5–7]. This phenomenon is very common in urothelial carcinoma of the bladder [8]. Here we describe two cases with multifocal recurrences of mucinous UrAC in the urothelium of the prostate and penile urethra.

1.1. Case 1

A 50-year-old male was referred to our hospital after transurethral resection (TUR) of the bladder dome for UrAC in 2017. Staging with fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT), CT of the chest, abdomen, and pelvis, and diagnostic laparoscopy with abdominal cytology revealed no signs of metastasis (cT3N0M0) or peritoneal spread [9,10]. The patient received neoadjuvant radiation followed by partial cystectomy with resection of the urachus and brachytherapy to the suture lines of the bladder. Pathological examination revealed an intestinal UrAC of 4 cm invading the detrusor muscle with a 7-mm margin to the detrusor resection site (ypT3NxMxR0 UrAC, Sheldon stage IIIa; Table 1). Figure 1 shows histological slides of the UrAC and the persistent urachal remnant. Following surgery, no signs of recurrence on urethrocystoscopy (UCS) and imaging were observed. At 11 mo after surgery, he presented with macroscopic hematuria and UCS showed a papillary lesion in the distal urethra. A biopsy was taken and pathological examination revealed recurrent adenocarcinoma. PET/CT and CT of the chest, abdomen, and pelvis were performed. PET/CT showed FDG uptake in the proximal and distal urethra without signs of lymph node or distant metastases. The FDG uptake in the proximal urethra was considered to be urine stasis because no lesions were seen there on UCS. A complete resection was planned, including a distal urethrectomy with frozen section. During this procedure the urethra was spatulated on the ventral side, which revealed a secondary tumor localization. Owing to this unexpected finding, UCS was performed and showed more than five papillary lesions covering the complete length of the urethra, including a lesion in the prostatic urethra (Fig. 2), which had emerged within 1 mo. No recurrent lesions were found in the bladder. Because of the multiple recurrences covering the complete length of the urethra, salvage cystoprostatectomy with en-bloc urethrectomy, an ileal conduit, and pelvic lymph-node dissection were performed. Pathological examination revealed multifocal localizations of intestinal adenocarcinoma of the urethra with invasion of the corpus spongiosum (foci varying between 3 and 10 mm in diameter; Figs. 3 and 4). The resection margins were free of tumor. In the prostate, bilateral adenocarcinoma of the prostate was found incidentally (pT2cN0, Gleason score 3 + 3, initial prostate-specific antigen 0.52 ng/ml). No residual malignancy was found in the bladder mucosa and none of the 27 lymph nodes were positive for any type of malignancy. A CT scan of the chest, abdomen, and pelvis at 5 mo after salvage surgery showed multiple liver metastases. The patient received six cycles of palliative chemotherapy with capcitabine and oxaliplatin. After initial stable disease, progression oc-

| Case | pT | R | MC | SCC | TTR (mo) | Treatment for recurrence | FU status |
|------|----|---|----|-----|---------|--------------------------|-----------|
| 1    | ypT3 | R0 | Yes | No  | 11      | Salvage CyP with urethrectomy | DOD at 38 mo after initial Dx |
| 2    | pT2 | R0–1 | Yes | No  | 96      | 1. Salvage CyP          | DOD at 198 mo after initial Dx |
|      |     |     |     |     |         | 2. RT to urethra        |           |
|      |     |     |     |     |         | 3. Urethrectomy         |           |
|      |     |     |     |     |         | 4. Local urethral resection |           |
|      |     |     |     |     |         | 5. Total penectomy       |           |
| 3    | pT2 | R0 | Yes | No  | 12      | 1. Multiple TURs         | DOD at 139 mo after initial Dx |
|      |     |     |     |     |         | 2. CyP                  |           |
| 4    | pT3 | R1 | Yes | No  | 14      | CyP and adjuvant RT      | NED at 92 mo after initial Dx |
| 5    | pT3 | R0 | No  | No  | 18      | CyP with urethrectomy    | No FU     |
| 6    | pT2 | R0 | No  | No  | 4       | TUR                     | NED at 15 mo after initial Dx |

R = radicality; R0 = radical resection; R1 = nonradical resection; MC = mucinous component; SCC = signet cell component; TTR = time to recurrence (from partial cystectomy to first urothelial recurrence); CyP = cystoprostatectomy; TUR = transurethral resection; RT = radiation therapy; FU = follow-up; DOD = death from disease; Dx = diagnosis; NED = no evidence of disease.

* Case 1 in this report.

| Case | pT | R | MC | SCC | TTR (mo) | Treatment for recurrence | FU status |
|------|----|---|----|-----|---------|--------------------------|-----------|
| 1    | ypT3 | R0 | Yes | No  | 11      | Salvage CyP with urethrectomy | DOD at 38 mo after initial Dx |
| 2    | pT2 | R0–1 | Yes | No  | 96      | 1. Salvage CyP          | DOD at 198 mo after initial Dx |
|      |     |     |     |     |         | 2. RT to urethra        |           |
|      |     |     |     |     |         | 3. Urethrectomy         |           |
|      |     |     |     |     |         | 4. Local urethral resection |           |
|      |     |     |     |     |         | 5. Total penectomy       |           |
| 3    | pT2 | R0 | Yes | No  | 12      | 1. Multiple TURs         | DOD at 139 mo after initial Dx |
|      |     |     |     |     |         | 2. CyP                  |           |
| 4    | pT3 | R1 | Yes | No  | 14      | CyP and adjuvant RT      | NED at 92 mo after initial Dx |
| 5    | pT3 | R0 | No  | No  | 18      | CyP with urethrectomy    | No FU     |
| 6    | pT2 | R0 | No  | No  | 4       | TUR                     | NED at 15 mo after initial Dx |
curred. After local radiation and second-line treatment with irinotecan, further progression was noted and the patient died 1 yr after the liver metastases were found.

1.2. Case 2

A search in our institutional database of 80 patients with UrAC diagnosed between October 1997 and August 2020 revealed 56 patients who were treated with TUR and partial cystectomy and had follow-up of >1 yr. Among these cases we identified a 55-yr-old male who was referred to our hospital in 2007 with signs of recurrent mucinous UrAC at the bladder neck/prostatic urethra. The patient was
initially treated with partial cystectomy for localized UrAC at another hospital in 1999. Pathological examination revealed a mucinous UrAC (pT2NxMxR0–1, Sheldon stage IIIa) of 12 cm in diameter (Table 1). It remained unclear if the initial resection was radical. No adjuvant therapy was given. At 8 yr after his initial surgery, the patient experienced a decrease in urinary flow and a mucinous discharge. UCS was performed and revealed mucinous tissue in the prostatic urethra close to the bladder neck. TUR was carried out and pathological examination revealed recurrence of mucinous UrAC in the prostatic urethra. Imaging showed no signs of metastasis. At our hospital, the patient underwent salvage cystoprostatectomy with an ileal conduit; no residual carcinoma was found in the specimen (pT0N0R0 in the urethra). At 10 mo after surgery, he developed a mucinous urethral discharge and a recurrence was found in the proximal urethra. Biopsy confirmed the presence of (recurrent) adenocarcinoma, which was treated with radiation to the proximal urethra and prostatic fossa (47 Gy) and an additional boost to the proximal urethra (70 Gy in total). The patient presented again 1 yr later with a mucinous discharge from the urethra and salvage (proximal) urethrectomy was performed. Imaging showed no signs of metastasis. Pathological examination of the urethrectomy specimen revealed multiple foci of mucinous UrAC in the lumen of the urethra with infiltrative growth into the corpus cavernosum at multiple sites. At 1 yr after urethrectomy, the patient experienced recurrence in the distal urethra, for which another local resection was performed (Fig. 5). Some 3 yr later, a FDG-PET/CT showed multifocal uptake in the penis suspicious of recurrence (Fig. 6). In addition, a FDG-avid inguinal lymph-node (left-side) and a lesion in corpus L1 suggestive of bone-metastasis were seen. Total penectomy was performed to minimize local symptoms. Mucinous adenocarcinoma was present in the corpora cavernosa and glans penis. The

2. Discussion

In both of our cases, the first manifestation of recurrent UrAC was found in the urethra. The mechanism underlying these urothelial UrAC recurrences in the prostatic and penile urethra remain unclear. Because the primary UrAC invaded through the bladder wall in both patients, it is possible that UrAC in the urethra manifested as local spread, as seen in multifocal urothelial carcinoma. UrAC in the urethra may also be regarded as local seeding, comparable to UrAC causing peritoneal metastases by invading the peritoneum and spreading mucinous tumor cells in the intra-abdominal cavity [4,7]. Another plausible explanation could be that these urethral UrAC recurrences were the first sign of local metastasis that subsequently progressed to nodal and organ metastases. Although the third explanation...
seems the most appropriate one, we cannot exclude the other two.

Follow-up of UrAC with imaging (mostly CT and/or PET/CT) after local curative treatment is generally performed because of the frequent local bladder-dome recurrences and, in particular, distant metastases [4,9]. Whether routine UCS should be performed after local treatment, as in urothelial cancer, is unknown. Since the occurrence of urethral UrAC is at most anecdotal and recurrence at the bladder dome can also be detected by imaging, it remains debatable whether routine surveillance with UCS is beneficial. In the two cases reported here, routine UCS did not detect the urethral recurrences, as symptoms (hematuria and a urethral mucinous discharge) prompted further investigation(s).

The optimal treatment strategy for urethral recurrence of UrAC is not known. Of the four cases with UrAC recurrence in the urethra previously described in the literature (Table 1), two patients were treated with cystoprostatectomy with or without urethrectomy and two were treated with TUR [5–7]. Five of the six patients had adequate follow-up data and two of them showed no evidence of disease in follow-up after secondary treatment (Table 1). This indicates that recurrences of UrAC can be cured. It remains a question whether extensive surgery will lead to better oncological outcome. The treatments given to our two patients were empirical and based in an expert center. Both patients received salvage therapy but were not cured by urethrectomy and finally developed distant metastases. We believe that a better understanding of the pathogenesis of UrAC and international collaboration among experts are needed to treat these rare recurrent urethral lesions caused by UrAC.

UrAC is an extremely rare disease that can be treated via partial cystectomy with en-bloc resection of the urachal remnant and umbilicus in the case of local disease. Recurrence after surgery has been described at the initial resection site (bladder dome), in lymph nodes, or as intra-abdominal spread (peritoneal metastases), and/or as organ metastases. Our two cases and the four comparable cases reported in the literature indicate that urothelial spread of UrAC is rare but possible. In the case of recurrent hematuria or mucinuria, UCS is recommended to detect any recurrence. Further research is needed to unravel the pathogenesis of these UrAC recurrences and to determine the best treatment strategy for recurrent urethral UrAC.

Conflicts of interest: The authors have nothing to disclose.

Ethics considerations: Appropriate ethical approval was obtained according to national regulations and the principles of the Declaration of Helsinki. The patients in this manuscript have given informed consent for publication of their case details. Institutional ethical guidelines were followed and approval was obtained (number: IRBd21-015).

Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.euros.2021.08.010.

References

[1] Collins DC, Velazquez-Kennedy K, Deady S, Brady AP, Sweeney P, Power DG. National incidence, management and survival of urachal carcinoma. Rare Tumors 2016;8:97–101.
[2] Sheldon CA, Clayman RV, Gonzalez R, Williams RD, Fraley EE. Malignant urachal lesions. J Urol 1984;131:1–8.
[3] Ashley RA, Inman BA, Sebo TJ, et al. Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer 2006;107:712–20.
[4] Szarvas T, Mdos O, Niedworok C, et al. Clinical, prognostic, and therapeutic aspects of urachal carcinoma. A comprehensive review with meta-analysis of 1,010 cases. Urol Oncol 2016;34:388–98.
[5] Gopalan A, Sharp DS, Fine SW, et al. Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol 2009;33:659–68.
[6] Ching CB, Chen L, Fergany A. Prostatic urethral recurrence of urachal adenocarcinoma. J Clin Oncol 2011;29:e736–8.
[7] Yasui T, Okamura T, Akita H, Kojima M, Kohri K. Urethral recurrence of urachal carcinoma: a case report. Int J Urol 1997;4:106–8.
[8] Balci U, Dogantekin E, Özer K, Görgel SN, Girgin C, Dincel C. Patterns, risks and outcomes of urethral recurrence after radical cystectomy for urothelial cancer: over 20 year single center experience. Int J Surg 2015;13:148–51.
[9] Stokkel LE, Stokkel MPM, Donswijk ML, et al. The diagnostic value of FDG-PET/CT for urachal cancer. Clin Genitourin Cancer In press. https://doi.org/10.1016/j.clgc.2021.03.002.
[10] Stokkel LE, Mehta AM, Behrendt MA, et al. Diagnostic laparoscopy and abdominal cytology reliably detect peritoneal metastases in patients with urachal adenocarcinoma. Ann Surg Oncol 2020;27:2468–75.